Yamanishi T, et al. - A randomized controlled study was designed to assess efficacy and safety of combination of tadalafil + mirabegron for overactive bladder/benign prostatic hyperplasia (OAB/BPH). Thy randomized a total of 176 male individuals with lower urinary tract symptoms (50 to 89 years), with remaining OAB symptoms even after administering tadalafil for more than 8 weeks to either tadalafil monotherapy group (5 mg/day) or tadalafil/mirabegron combination therapy group (5 mg/50 mg/day). They obtained similar baseline characteristics of individuals in the two groups. It was noted that impact of tadalafil/mirabegron combination therapy on relieving OAB symptoms seemed to be greater than that of tadalafil monotherapy and can be safely applied.